Radiopharmaceuticals and Tracers

This channel includes news and new technology innovations for nuclear and molecular imaging agents, radiotracers and radiopharmaceuticals used in PET or SPECT imaging. This includes advances in myocardiac perfusion agents.

First participant of cohort 4 of the theranostic CL04 trial investigating 64Cu/67Cu SARTATE in neuroblastoma has been treated at the highest dose cohort of 375MBq/kg body weight using NorthStar’s electron accelerator-produced Cu-67, marking a key milestone in NorthStar’s agreement to exclusively supply Cu-67 to Clarity
News | Radiopharmaceuticals and Tracers
First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma

August 29, 2023 — NorthStar Medical Radioisotopes, LLC (“NorthStar"), a global innovator in the development, production ...

Time August 29, 2023
arrow
First participant of cohort 4 of the theranostic CL04 trial investigating 64Cu/67Cu SARTATE in neuroblastoma has been treated at the highest dose cohort of 375MBq/kg body weight using NorthStar’s electron accelerator-produced Cu-67, marking a key milestone in NorthStar’s agreement to exclusively supply Cu-67 to Clarity
News | Radiopharmaceuticals and Tracers
Carolina Breast Imaging Specialists, PLLC Is First in Nation to Adopt Groundbreaking Imagio Breast Imaging System for Breast Cancer Diagnosis

August 29, 2023 — Mammograms are an essential part of preventive healthcare, and when an initial review reveals a ...

Time August 29, 2023
arrow
Strategic collaboration signed to support the development of radiopharmaceuticals in the fight against cancer
News | Radiopharmaceuticals and Tracers
PanTera and TerraPower Isotopes Join Forces to Accelerate Access to Actinium-225

August 28, 2023 — TerraPower Isotopes and PanTera, the Belgian joint venture created by SCK CEN and IBA, announced that ...

Time August 28, 2023
arrow
FDA-approved in May 2023, POSLUMA is commercially available through 36 radiopharmacies across the United States
News | Prostate Cancer
Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer

July 28, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 28, 2023
arrow
A collaboration to advance development of a fibroblast activation protein (FAP)-targeted PET diagnostic compound for a broad array of epithelial-derived cancers. 
News | Radiopharmaceuticals and Tracers
Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

July 25, 2023 — Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative ...

Time July 25, 2023
arrow
Guerbet, a global specialist in contrast media and medical imaging solutions, announced the success of its teams at the PI-CAI (Prostate Imaging: Cancer Al) Grand Challenge
News | Prostate Cancer
Guerbet Wins PI-CAI Grand Challenge on Detection of Prostate Cancer

July 19, 2023 — Guerbet, a global specialist in contrast media and medical imaging solutions, announced the success of ...

Time July 19, 2023
arrow
A collaboration to advance development of a fibroblast activation protein (FAP)-targeted PET diagnostic compound for a broad array of epithelial-derived cancers
News | Radiopharmaceuticals and Tracers
First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

July 11, 2023 — Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative ...

Time July 11, 2023
arrow
Coronary computed tomography angiography is a cheaper, less-invasive alternative to intravascular ultrasound in pharmaceutical clinical trials
Feature | Cardiac Imaging | By Matthew Jay Budoff, MD, FACC, FAHA
The Benefits of Coronary CTA in Pharmaceutical Clinical Trials

Coronary computed tomography angiography (CCTA) is cheaper, easier to use and its results are easier to understand than ...

Time July 11, 2023
arrow
NorthStar’s high purity non-carrier-added (n.c.a.) Ac-225 to be used in advancing Nucleus’ partners radioligand therapies to treat cancer
News | Molecular Imaging
NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)

July 5, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time July 05, 2023
arrow
Cardinal Health Nuclear & Precision Health Solutions (NPHS) (Booth #2041) will feature information on radiotherapies and theranostics readiness at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2023 Annual Meeting.
News | SNMMI
Cardinal Health Highlights Nuctrac Theranostic Module, Theranostics Readiness at SNMMI 2023

June 23, 2023 — Cardinal Health Nuclear & Precision Health Solutions (NPHS) (Booth #2041) will feature information on ...

Time June 23, 2023
arrow
Therapeutically equivalent and fully substitutable to Kinevac (Sincalide for Injection) formulated, filled and packaged in the United States provides health care facilities with choice and value
News | Contrast Media
Fresenius Kabi Broadens Radiology Portfolio with its First-to-Market Authorized Generic, Sincalide for Injection

June 21, 2023 — Fresenius Kabi, a leading provider of injectable medicines, announced today it has launched the ...

Time June 21, 2023
arrow
POSLUMA is now commercially available in multiple U.S. radiopharmacies, with nationwide availability by end of June 2023
News | Prostate Cancer
Blue Earth Diagnostics and PETNET Solutions Inc, A Siemens Healthineers Company, Announce U.S. Commercial Availability of POSLUMA (Flotufolastat F 18) Injection for PET Imaging of Prostate Cancer

June 21, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time June 21, 2023
arrow
Planned transition part of NorthStar’s strategy for continued growth and industry leadership in domestic radioisotope production and radiopharmaceutical development to meet needs of patients, pharmaceutical companies and radiopharmacies
News | Radiopharmaceuticals and Tracers
NorthStar Medical Technologies, LLC Appoints Frank Scholz, PhD, as President and Chief Executive Officer

June 19, 2023 — NorthStar Medical Technologies, LLC, a global innovator in the development, production and ...

Time June 19, 2023
arrow
The first patient has been scanned in a Phase I clinical trial for an investigational fluorine-18 (18F) CD8-targeted imaging radiopharmaceutical
News | Radiopharmaceuticals and Tracers
First Ever Investigational 18F-CD8 PET Radiopharmaceutical Aims to Predict and Monitor Early Response to Cancer Immunotherapies

June 15, 2023 — With immunotherapy emerging as one of the most important treatment options in oncology, GE HealthCare ...

Time June 15, 2023
arrow
POSLUMA (flotufolastat F 18) PET/CT image showing uptake in the prostate gland, consistent with primary prostate cancer Photo courtesy of Blue Earth Diagnostics
News | Radiopharmaceuticals and Tracers
U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

May 30, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 30, 2023
arrow
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 in recurrent prostate cancer
News | Prostate Cancer
Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

May 2, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of ...

Time May 02, 2023
arrow
GE HealthCare will deliver the Cyclotrons to ALISA’s laboratory facility in Midrand, South Africa early next year, giving patients in Africa access to medical advancements
News | PET Imaging
GE HealthCare and Axim Life Isotopes South Africa (ALISA) Collaborate to Expand Access to Molecular Imaging in South Africa and Drive Precision Care

April 28, 2023 — GE HealthCare to deliver two Cyclotrons next year, expanding South Africa’s capacity to produce ...

Time April 28, 2023
arrow
NorthStar Medical Radioisotopes has expanded its management team with the appointment of Jean-Noel David, MBA, MS, as Vice President, Operations.
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Expands Management Team with Appointment of Jean-Noel David, MBA, MS, as Vice President, Operations

April 24, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time April 24, 2023
arrow
NorthStar Medical Radioisotopes has promoted Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies.
News | Molecular Imaging
NorthStar Medical Radioisotopes Announces Promotion of Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies

April 13, 2023 —NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time April 13, 2023
arrow
New radiopharmaceutical Contract Development and Manufacturing Organization (CDMO/CMO) provides powerhouse combination of capabilities and expertise to advance patient care
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

April 3, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time April 03, 2023
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now